9 results
2021 ACR/VF Guidelines for Management of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

#Granulomatosis #Polyangiitis #GPA
2021 ACR/VF Guidelines ... for Management ... of Granulomatosis ... #rheumatology # ... algorithm #vasculitis
2021 ACR/VF Guidelines for Management of Eosinophilic Granulomatosis with Polyangiitis (EGPA)

#EGPA #Eosinophilic #Granulomatosis #Polyangiitis #ACR2021 #Management
2021 ACR/VF Guidelines ... for Management ... with Polyangiitis ... #rheumatology # ... algorithm #vasculitis
ANCA-Associated Vasculitis
There are many definitions, but most come down to the presence of granulomas (pathologically or
with polyangiitis ... with polyangiitis ... ANCA #Vasculitis #differential ... #diagnosis #algorithm ... #rheumatology
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
- ACR/VF 2021 Guidelines ... Nodosa (PAN) • Granulomatosis ... • Eosinophilic Granulomatosis ... ACR2021 #Guidelines #algorithm ... #rheumatology
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Granulomatosis with ... ANCA Vasculitis Management ... Algorithm - ACR ... ANCA #Vasculitis #Management ... #rheumatology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
Eosinophilic Granulomatosis ... with Polyangiitis ... Algorithm - ACR ... #Polyangiitis # ... #rheumatology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Incidence: common in APL ... initiation • Differential ... APML #diagnosis #management ... #hematology #oncology
There are similarities and differences between these 3 conditions which all carry treatment implications. Each mimic
conditions which all ... Therefore, in all ... #diagnosis #differential ... #algorithm #management ... #treatment #criticalcare
Hodgkin's Lymphoma Overview

Hodgkin's lymphoma (HL) is an uncommon hematological malignancy arising from mature B cells. It
accounts for 10% of all ... Immunohistochemical studies (to differentiate ... classification #hematology ... #oncology #management